1-10 of 10
Wendy Deenik
Close
Sort by
Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1889.
https://doi.org/10.1182/blood-2018-99-116920
Published: 2018
Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Claudia A.M. Stege, MD, Bronno van der Holt, Ulf-Henrik Mellqvist, MD, Mark-David Levin, PhD, Morten Salomo, Niels Abildgaard, MD, Gerard Bos, MDPhD, Heleen Visser-Wisselaar, Markus Hansson, MD PhD, Annette van der Velden, MD, Wendy Deenik, MD, Astrid Gruber, MD PhD, Jules L.L.M. Coenen, MD, Torben Plesner, MD, Saskia Klein, MD, Bea Tanis, MD PhD, Damian L. Szatkowski, MDPhDMSc, Rolf Brouwer, MD PhD, Matthijs Westerman, MD, Maria Berhardina Leijs, MD, Harm Sinnige, Einar Haukaas, Klaas van der Hem, MD PhD, Marc Durian, MD, Vera Mattijssen, MD PhD, Peter Gimsing, DO, PhD, Niels WCJ Van De Donk, Marian Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3146.
https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146
Published: 2017
Journal Articles

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Saskia K. Klein, MD PhD, Esther G.M. De Waal, MD, Corien M. Eeltink, RN, MA, ANP, Paula F. Ypma, MD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD PhD, Bea Tanis, MD PhD, Monique S. Slee-Valentijn, MD, Monique Minnema, Heleen Visser-Wisselaar, PhD, Claudia Stege, MD, Niels W.C.J. van de Donk, MD PhD, Kazem Nasserinejad, MA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3305.
https://doi.org/10.1182/blood.V128.22.3305.3305
Published: 2016
Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Arjan A. van de Loosdrecht, MD PhD, Dana A Chitu, PhD, Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Heleen Visser-Wisselaar, PhD, Annelies Verbrugge, Petra Muus, MD PhD, Inge de Greef, MD PhD, Pierre W Wijermans, MD, Joop H. Jansen, PhD, Saskia K. Klein, MD PhD, Edo Vellenga, MD PhD, Marie-Cecile Legdeur, MD PhD, Wendy Deenik, MD PhD, Mojca jongen-Lavrencic, MD PhD, Rien van Marwijk-Kooy, Bea Tanis, MD PhD, Jurgen Wegman, Tanja van Maanen, Gert Ossenkoppele, MD PhD
Journal: Blood
Blood (2016) 128 (22): 224.
https://doi.org/10.1182/blood.V128.22.224.224
Published: 2016
Journal Articles

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Clinical Trials & Observations
Sonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard M. J. Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, Wendy Deenik, Astrid Gruber, Juleon L. L. M. Coenen, Torben Plesner, Saskia K. Klein, Bea C. Tanis, Damian L. Szatkowski, Rolf E. Brouwer, Matthijs Westerman, M. (Rineke) B. L. Leys, Harm A. M. Sinnige, Einar Haukås, Klaas G. van der Hem, Marc F. Durian, E. (Vera) J. M. Mattijssen, Niels W. C. J. van de Donk, Marian J. P. L. Stevens-Kroef, Pieter Sonneveld, Anders Waage
Journal: Blood
Blood (2016) 127 (9): 1109–1116.
https://doi.org/10.1182/blood-2015-11-679415
Published: 2016
Includes: Supplemental data
Journal Articles

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

Sonja Zweegman, MDPhD, Bronno van der Holt, PhD, Ulf-Henrik Mellqvist, MDPhD, Morten Salomo, MD, Gerard M.J. Bos, MDPhD, Mark-David Levin, MDPhD, Heleen A Visser-Wisselaar, PhD, Markus Hansson, MD PhD, Annette WG van der Velden, MD, Wendy Deenik, MDPhD, Astrid Gruber, MDPhD, Juleon LLM Coenen, MD, Torben Plesner, MD, Saskia K Klein, MDPhD, Bea Tanis, MDPhD, Damian L Szatkowski, MDPhDMSc, Rolf Brouwer, MDPhD, Matthijs Westerman, MD, M (Rineke) BL Leys, MDPhD, Niels W.C.J. van de Donk, MDPhD, Einar Haukås, MD, Klaas van der Hem, MD PhD, MF Durian, MD, E (Vera) JM Mattijssen, MDPhD, Harm AM Sinnige, MDPhD, Marian JPL Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD
Journal: Blood
Blood (2014) 124 (21): 179.
https://doi.org/10.1182/blood.V124.21.179.179
Published: 2014
Journal Articles

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib

Wendy Deenik, Bronno van der Holt, Jeroen J. W. M. Janssen, Isabel W. T. Chu, Peter J. M. Valk, Gert J. Ossenkoppele, Ilse P. van der Heiden, Pieter Sonneveld, Ron H. N. van Schaik, Jan J. Cornelissen
Journal: Blood
Blood (2010) 116 (26): 6144–6145.
https://doi.org/10.1182/blood-2010-07-296954
Published: 2010
Journal Articles

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

Wendy Deenik, MD, Bronno van der Holt, PhD, Jeroen JWM Janssen, MD, Isabel W.T. Chu, Peter Valk, PhD, Gert Ossenkoppele, MD, PhD, Ilse van der Heiden, Pieter Sonneveld, MD, PhD, Ron van Schaik, PhD, Jan J. Cornelissen, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2208.
https://doi.org/10.1182/blood.V114.22.2208.2208
Published: 2009
Journal Articles

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.

Jeroen J.W.M. Janssen, MD, Wendy Deenik, Karlijn G.M. Smolders, Monique Terwijn, Angele Kelder, J. J. Cornelissen, Gerrit-Jan Schuurhuis, Gert J. Ossenkoppele
Journal: Blood
Blood (2009) 114 (22): 3245.
https://doi.org/10.1182/blood.V114.22.3245.3245
Published: 2009
Journal Articles

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

Clinical Trials & Observations
Wendy Deenik, Bronno van der Holt, Gregor E. G. Verhoef, Willem M. Smit, Marie J. Kersten, Hanneke C. Kluin-Nelemans, Leo F. Verdonck, Augustin Ferrant, Anton V. M. B. Schattenberg, Jeroen J. W. M. Janssen, Pieter Sonneveld, Marinus van Marwijk Kooy, Shulamit Wittebol, Roelof Willemze, Pierre W. Wijermans, Petra H. M. Westveer, H. Berna Beverloo, Peter Valk, Bob Löwenberg, Gert J. Ossenkoppele, Jan J. Cornelissen
Journal: Blood
Blood (2008) 111 (5): 2581–2588.
https://doi.org/10.1182/blood-2007-08-107482
Published: 2008